|Country||Type of vaccine||Leading Institute||Immunological strategy||Stage of development||Comments/limitations and possible side effects|
|Argentina||Junin virus (JUNV) vaccine against Argentinian hemorrhagic fever||National Institute of Human Viral Diseases (ANLIS), Argentina||Cell culture with the virus molecular constructs .||
Based on phase 3, Clinical Trial: Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina is authorized for marketing in Argentina. Immunogenicity and safety |
No Clinical Trial Registry.
FDA’s Investigational New Drug Application #2257
|With the use of the vaccine in high-risk individuals, AHF incidence has declined, but cases continue to be reported .|
|Brazil||Tetravalent Dengue Vaccine||Butantan and the National Institutes of Health (NIH)||Live attenuated tetravalent DEN virus to provide immunity to each of the four serotypes of DEN ||
NCT02406729, Phase 3, Ongoing.|
NCT01696422, Phase 2 results demonstrated safety and induced robust, balanced, neutralizing antibody responses against the four DENV serotypes, in both naive and pre-exposed volunteers, after a single dose .
Limitation of the previous unique vaccine approved CYD-DTV has shown that age and previous exposure status of vaccine recipients to dengue virus had a significant|
effect on the safety and efficacy of the vaccine . The tetravalent vaccine expects to overcome this limitation.
|Zika Vaccine||Butantan Institute||
Live, DENV-vectored vaccine expressing pre membrane/|
membrane and envelope proteins
Purified inactivated virus
|Early-stage research |
Purified inactivated virus|
|Colombia||Malaria SPf66 vaccine||Malaria Vaccine and Drug Development Center, Colombia||Synthetic vaccine against the asexual blood stages of Plasmodium falciparum||
No registry in Clinicaltrials.gov|
Results published concluded that synthetic SPf66 vaccine may be used as a safe and highly immunogenic vaccine, suitable to protect high-risk populations such as children under 5 years of age resident in hyper- and holo-endemic areas, such as Africa or some regions of Latin America 
|A posterior Cochrane systematic review reported no evidence for protection by SPf66 vaccines against P. falciparum in Africa and a modest reduction in attacks of P. falciparum in South America. Further research with SPf66 vaccines in South America or with new formulations of SPf66 may be justified |
|Malaria vaccine against Plasmodium vivax||Malaria Vaccine and Drug Development Center, Colombia||Vaccine derived from the synthetic CS protein of Plasmodium vivax||NCT02083068, Phase II, completed, no results posted|
|Mexico||Vacuna Antipoliomielítica Bivalente Oral||Birmex||
Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexican Newborns. Status Unknown